Four Decades of Orphan Drugs and Priorities for the Future.

Autor: Sinha MS; From the Center for Health Law Studies, Saint Louis University School of Law, St. Louis (M.S.S.); Harvard Business School and the Harvard-MIT Center for Regulatory Science - both in Boston (A.D.S.); Hasso Plattner Institute, University of Potsdam, Potsdam, Germany (A.D.S.); and Duke Law School and the Duke-Margolis Center for Health Policy, Durham, NC (A.K.R.)., Stern AD; From the Center for Health Law Studies, Saint Louis University School of Law, St. Louis (M.S.S.); Harvard Business School and the Harvard-MIT Center for Regulatory Science - both in Boston (A.D.S.); Hasso Plattner Institute, University of Potsdam, Potsdam, Germany (A.D.S.); and Duke Law School and the Duke-Margolis Center for Health Policy, Durham, NC (A.K.R.)., Rai AK; From the Center for Health Law Studies, Saint Louis University School of Law, St. Louis (M.S.S.); Harvard Business School and the Harvard-MIT Center for Regulatory Science - both in Boston (A.D.S.); Hasso Plattner Institute, University of Potsdam, Potsdam, Germany (A.D.S.); and Duke Law School and the Duke-Margolis Center for Health Policy, Durham, NC (A.K.R.).
Jazyk: angličtina
Zdroj: The New England journal of medicine [N Engl J Med] 2024 Jul 11; Vol. 391 (2), pp. 100-102. Date of Electronic Publication: 2024 Jul 06.
DOI: 10.1056/NEJMp2401487
Databáze: MEDLINE